IDH-wildtype glioblastoma

This study tests whether adding the drug selinexor to standard chemotherapy (temozolomide) can better control recurrent glioblastoma, an aggressive brain cancer. About 97 adults whose tumor has returned after initial treatment will receive either the combo or chemotherapy alone. …

This early-phase trial tests the safety of a drug called ERAS-801 in 10 adults with recurrent glioblastoma, a fast-growing brain cancer. The drug targets a protein called EGFR that is overactive in many of these tumors. Researchers will also check if the drug affects tumor activi…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This early-stage trial tests a new treatment for adults with a returning, aggressive brain cancer called glioblastoma. The therapy uses the patient's own immune cells, modified to recognize and attack the cancer, and delivers them directly into the brain. The main goals are to se…

This phase III trial tests a new way to deliver radiation called TMPRT, which gives the total dose in short pulses with breaks in between, for people with a newly diagnosed, aggressive brain cancer (MGMT-unmethylated glioblastoma). About 398 adults will be randomly assigned to ge…

This early-stage trial tests two drugs—triapine and temozolomide—together in people whose glioblastoma has returned. The goal is to find the safest dose and see how well patients tolerate the combination. About 30 adults with recurrent grade 2-4 glioma will take part.

This early-phase trial is testing a new drug called M3554, which is designed to seek out and attack cancer cells that have a protein called GD2 on their surface. The study will include up to 52 people with advanced soft tissue sarcoma or glioblastoma that has not responded to pri…

This clinical trial is testing whether adding an experimental drug called WSD0922-FU to standard chemotherapy (temozolomide) can better slow the growth of a specific type of brain cancer called EGFR-mutant glioblastoma. The study involves about 60 adults whose tumors have a parti…

This early-phase trial tests the safety and best dose of the drug triapine when given together with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine works by blocking enzymes that cancer cells need to grow, while radiation kills cancer cells …

This study tests a new drug (Debio 0123) combined with standard chemotherapy (temozolomide) and sometimes radiation in adults with glioblastoma, an aggressive brain cancer. The goal is to find the safest dose and see if the combination helps people live longer. About 116 particip…

This study tests whether a continuous glucose monitor (CGM) can help people with glioblastoma, a severe brain cancer, manage their blood sugar levels and potentially live longer. High blood sugar during treatment is linked to worse outcomes, often caused by steroids. The CGM devi…

This trial tests a new approach for glioblastoma, an aggressive brain cancer. A device implanted in the skull uses ultrasound to temporarily open the blood-brain barrier, allowing immune-boosting drugs to reach the tumor. The study involves 25 adults who have completed radiation,…

This early-phase trial tests the safety of a new treatment for people with recurrent or progressive high-grade glioma, a serious brain cancer. The therapy uses the patient's own immune cells, modified in a lab to recognize and attack tumor cells, and delivers them directly into t…

This study tests a new drug called LMP744 in people whose glioblastoma has come back after standard treatment. The drug is designed to kill cancer cells by blocking a key growth signal and interfering with DNA repair. Participants will receive the drug through a vein for 5 days e…

This study tests whether combining pembrolizumab, olaparib, and temozolomide can shrink or slow the growth of gliomas that have come back after treatment. About 57 adults with a specific type of glioma (IDH-mutated, grade II or III) will receive the drug combination. The goal is …

This trial tests whether adding the drug WP1066 to standard radiation therapy can help people with newly diagnosed glioblastoma, a fast-growing brain cancer. WP1066 targets a protein called STAT3 that helps tumors grow and hide from the immune system. The study will enroll 39 pat…

This phase 2 trial tests whether adding DOC1021, a personalized dendritic cell vaccine, to standard treatment (surgery, chemo, radiation) improves survival in adults newly diagnosed with glioblastoma. About 180 participants will be randomly assigned to receive the vaccine plus st…

This study tests two drugs—retifanlimab (an immunotherapy) and DFMO (a growth blocker)—alone or together in 33 adults with progressive high-grade glioma, an aggressive brain cancer. The goal is to find the safest, most effective dose and see if the combination boosts the immune s…

This study is for adults with recurrent glioblastoma, an aggressive brain cancer. It tests whether adding a precise type of radiation (stereotactic radiosurgery guided by a special PET scan) to a device that delivers electric fields to the brain (TTFields) helps people live longe…

This early-phase trial is testing a new radioactive drug, [177Lu]Lu-DOTA-EB-RGD2, in 24 patients with recurrent high-grade glioma, a fast-growing brain cancer. The drug is designed to seek out and deliver radiation directly to tumor blood vessels. It can be given through a vein o…

This early-phase trial tests a single dose of a radioactive drug called [177Lu]Lu-XT771 in people with recurrent glioblastoma, an aggressive brain cancer. The drug is injected directly into the cavity left after tumor removal surgery, aiming to deliver radiation precisely to canc…

This early-phase study tests a radioactive drug called 177Lu-PSMA-617 combined with standard chemotherapy (temozolomide) for people with aggressive IDH wild type gliomas. The goal is to see if the combination is safe and to get a first look at whether it helps control tumor growt…

This phase III trial is testing whether delivering the drug bevacizumab (Avastin) directly to the brain through a catheter, along with standard chemo and radiation, can help people with newly diagnosed glioblastoma live longer. The study will enroll 432 adults with this aggressiv…

This study tests whether giving a higher dose of radiation along with a drug called bevacizumab can help people with a fast-growing brain tumor (glioblastoma) live longer. About 146 adults aged 18 to 70 with a specific type of glioblastoma will receive the treatment. The goal is …

This early-phase trial tests a drug called WSD0628, which blocks a DNA repair protein, given together with radiation therapy for people whose high-grade glioma (a type of brain tumor) has come back after previous treatment. The study aims to find the safest dose and see if the co…

This Phase 3 trial tests whether adding lomustine to standard temozolomide chemotherapy improves survival for people with newly diagnosed glioblastoma that has a specific genetic marker (MGMT methylated). About 200 adults aged 18-70 will be randomly assigned to receive either the…

This phase 2 trial tests a new drug called GI-102, alone or with the immunotherapy pembrolizumab, given before surgery to people with recurrent or progressive glioblastoma (a fast-growing brain cancer). The goal is to see if these drugs can increase cancer-fighting immune cells i…

This early-stage trial tests whether stem cells taken from fat tissue can be safely injected into the brain during surgery for recurrent glioblastoma. The stem cells are meant to attack remaining tumor cells and make them more sensitive to chemotherapy. About 20 adults whose brai…

This study tests whether adding two experimental drugs, DB107-RRV and DB107-FC, to standard treatment (radiation and chemotherapy) can help people with newly diagnosed high grade glioma, a fast-growing brain cancer. About 70 adults aged 18-75 will receive the drugs during and aft…

This early-phase trial tests a new treatment called P134 cells for people with recurrent glioblastoma, an aggressive brain cancer that has come back. P134 cells are immune cells engineered to target two proteins (CD44 and CD133) found on tumor cells. The study will enroll 26 adul…

This trial is testing two experimental drugs, avutometinib and defactinib, alone or with a standard chemotherapy (temozolomide), in people with high-grade malignant brain tumours like glioblastoma. The study aims to find a safe dose and see if the drugs can shrink tumours or stop…

This study tests two immunotherapy drugs, efineptakin alfa and pembrolizumab, in people whose glioblastoma (a type of brain cancer) has returned after standard treatment. The goal is to see if this combination can help the immune system fight the tumor and improve survival. About…

This study tests whether adding silibinin (a milk thistle extract) to standard chemoradiation and maintenance chemotherapy can delay tumor growth in people with a specific type of newly diagnosed glioblastoma. About 110 adults whose tumors have a certain protein marker (STAT3-pos…

This phase 2 trial is testing whether adding the diabetes drug metformin to standard radiation and chemotherapy can help people with a specific type of glioblastoma, a fast-growing brain cancer. The study will include about 64 patients whose tumors have a particular energy-making…

This early-stage trial is testing a combination of two immunotherapy drugs, D2C7-IT and 2141-V11, for people with recurrent glioblastoma, a fast-growing brain cancer. The treatment is delivered directly into the brain after surgery, followed by injections near the neck to boost t…

This study tests two experimental immunotherapy drugs, D2C7-IT and 2141-V11, in adults with a newly diagnosed, aggressive type of brain cancer called glioblastoma. The drugs are given directly into the brain after surgery, followed by injections near the neck lymph nodes. The goa…

This early-phase trial tests the drug troriluzole in 27 adults with recurrent IDH wild-type glioblastoma, an aggressive brain cancer. Participants take the drug before surgery, and researchers measure brain activity and glutamate levels in the removed tumor tissue. The goal is to…

Researchers are testing a radioactive tracer called FMISO with PET/MRI scans to map oxygen levels inside malignant brain tumors. Adults with a suspected glioma receive the tracer by IV, then undergo brain scans that combine PET and MRI, sometimes with contrast dyes. The study che…

This study is testing whether chemical marks on RNA molecules found in blood and urine can help diagnose gliomas, a type of brain tumor. Researchers will collect samples from 228 adults scheduled for brain surgery and compare them to healthy controls. The goal is to develop a non…

This pilot study looks at whether taking the chemotherapy drug temozolomide at a specific time of day (morning or evening) is practical for people with glioblastoma, a type of brain cancer. Fifty adults who have completed surgery and radiation will be randomly assigned to take th…

This study is testing a new technology called SmartMatch that analyzes tumor tissue from people with recurrent brain or spinal cord tumors. The goal is to see if SmartMatch can quickly identify which drugs might work best for each person's specific tumor. About 80 participants ag…

This study tracks mental health and suicide risk in 176 adults with glioblastoma, a serious brain cancer. Participants fill out questionnaires about depression, anxiety, quality of life, and suicidal thoughts. The goal is to understand what factors increase suicide risk in these …

This phase II trial is testing whether advanced imaging techniques like DSC-MRI and PET scans can better distinguish actual tumor growth from treatment-related changes in people with newly diagnosed glioblastoma. The study will enroll 100 adults who are receiving standard treatme…

This study is testing a new approach to personalize treatment for people with a fast-growing brain tumor called glioblastoma. Researchers will use a lab test on tumor cells to see which drugs might work best for each patient. The goal is to find out if this method can help more p…

This study is testing whether a personalized approach to choosing cancer drugs can help people with glioblastoma, an aggressive brain tumor. Researchers will take tumor tissue from each patient, grow the cells in a lab, and test many drugs to find which ones work best. Then, pati…